This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Dividendos de Sigilon Therapeutics

Dividendo controles de criterios 0/6

Sigilon Therapeutics does not have a record of paying a dividend.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria	2.8%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-US$12.03
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet

Apr 17

Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M

Aug 04

Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer

Jun 14

What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?

Mar 04

Sigilon Therapeutics' MPS-1 gene therapy an Orphan Drug in U.S.

Dec 17

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: Insufficient data to determine if SGTX's dividends per share have been stable in the past.

Dividendo creciente: Insufficient data to determine if SGTX's dividend payments have been increasing.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Sigilon Therapeutics vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de SGTX con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (SGTX)	n/a
Suelo de mercado 25% (US)	1.5%
Techo de mercado 25% (US)	4.7%
Media de la industria (Biotechs)	2.8%
Previsión de analistas en 3 años (SGTX)	n/a

Dividendo destacado: Unable to evaluate SGTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Alto dividendo: Unable to evaluate SGTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Pago de beneficios a los accionistas

Cobertura de los beneficios: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: Unable to calculate sustainability of dividends as SGTX has not reported any payouts.

This company has been acquired

Dividendos de Sigilon Therapeutics

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Sigilon Therapeutics, Inc. Announces Board Changes

Sigilon Therapeutics, Inc.(NasdaqGS:SGTX) dropped from S&P TMI Index

Sigilon Announces Reverse Stock Split of Common Stock to Satisfy the Minimum Price Requirement for Continued Listing on the Nasdaq Global Select Market

Consensus EPS estimates fall by 12%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet

Consensus EPS estimates upgraded to US$0.81 loss

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Sigilon Therapeutics, Inc. Terminates the Employment of May Orfali as Chief Medical Officer

Price target decreased to US$2.88

Sigilon Therapeutics Receives Non-Compliance Notice from The Nasdaq Global Select Market

Consensus revenue estimates increase by 10%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to US$4.50

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Sigilon Therapeutics, Inc. Announces Resignation of Brooke Story from Her Position as Member of the Board of Directors and Any Committees Thereof

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M

Sigilon Therapeutics, Inc.(NasdaqGS:SGTX) dropped from Russell 2500 Value Index

Sigilon Therapeutics Receives Non-Compliance Notice from Nasdaq

Sigilon Therapeutics Receives Non-Compliance Notice from Nasdaq

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$4.12

Sigilon Therapeutics, Inc., Annual General Meeting, May 26, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Sigilon Therapeutics, Inc. Appoints Josias Fantato De Pontes as Treasurer

Price target increased to US$7.50

Price target increased to US$7.81

Sigilon Therapeutics, Inc Announces Update on SIG-001 Phase 1/2 Study in Hemophilia A

Third quarter 2021 earnings released: US$0.63 loss per share (vs US$2.47 loss in 3Q 2020)

Sigilon Therapeutics, Inc. Announces Acceptance of Clinical Trial Application in the UK for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

Second quarter 2021 earnings released: US$0.65 loss per share (vs US$2.54 loss in 2Q 2020)

Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases

Independent Director exercised options and sold US$66k worth of stock

CFO & Treasurer Glenn Reicin has left the company

Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer

Co-Founder notifies of intention to sell stock

Consensus forecasts updated

First quarter 2021 earnings released: US$0.60 loss per share (vs US$2.56 loss in 1Q 2020)

Chief Operating Officer has left the company

Chief Operating Officer has left the company

Consensus EPS estimates increase to -US$2.50

Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease

What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?

Sigilon Therapeutics, Inc. Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

Sigilon Therapeutics' MPS-1 gene therapy an Orphan Drug in U.S.

Sigilon Therapeutics, Inc. has completed an IPO in the amount of $126 million.

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies